Advertisement for orthosearch.org.uk
Results 1 - 5 of 5
Results per page:
Bone & Joint 360
Vol. 10, Issue 5 | Pages 12 - 13
1 Oct 2021


Bone & Joint 360
Vol. 6, Issue 5 | Pages 42 - 44
1 Oct 2017
Ross A


Bone & Joint Research
Vol. 2, Issue 3 | Pages 58 - 65
1 Mar 2013
Johnson R Jameson SS Sanders RD Sargant NJ Muller SD Meek RMD Reed MR

Objectives

To review the current best surgical practice and detail a multi-disciplinary approach that could further reduce joint replacement infection.

Methods

Review of relevant literature indexed in PubMed.


The Bone & Joint Journal
Vol. 95-B, Issue 11 | Pages 1581 - 1581
1 Nov 2013
Cook TM

We welcome letters to the Editor concerning articles that have recently been published. Such letters will be subject to the usual stages of selection and editing; where appropriate the authors of the original article will be offered the opportunity to reply.


The Journal of Bone & Joint Surgery British Volume
Vol. 90-B, Issue 6 | Pages 814 - 820
1 Jun 2008
Chu CR Izzo NJ Coyle CH Papas NE Logar A

We have studied the effects of bupivacaine on human and bovine articular chondrocytes in vitro. Time-lapse confocal microscopy of human articular chondrocytes showed > 95% cellular death after exposure to 0.5% bupivacaine for 30 minutes. Human and bovine chondrocytes exposed to 0.25% bupivacaine had a time-dependent reduction in viability, with longer exposure times resulting in higher cytotoxicity. Cellular death continued even after removal of 0.25% bupivacaine. After exposure to 0.25% bupivacaine for 15 minutes, flow cytometry showed bovine chondrocyte viability to be 41% of saline control after seven days. After exposure to 0.125% bupivacaine for up to 60 minutes, the viability of both bovine and human chondrocytes was similar to that of control groups.

These data show that prolonged exposure 0.5% and 0.25% bupivacaine solutions are potentially chondrotoxic.